Author | Richard S. Finn, MD

Articles

Second-Line Regorafenib Extends Survival in Sorafenib-Tolerant HCC Patients

January 21, 2017

This video examines an exploratory analysis of the RESORCE trial, which tested regorafenib vs placebo in hepatocellular carcinoma patients following radiographic progression on sorafenib.